Tell your provider if you are pregnant/breastfeeding, have a history of cancer, autoimmune disease, or take prescription medications (especially immunosuppressants or anticoagulants), and report any persistent or severe symptoms right away
2221, National Institutes of Health
National Law Review (Polsinelli PC) was explicit on April 22, 2026: removing a Category 2 bulk drug substance does not, on its own, authorize use of that substance in compounding or bring it within FDAs interim enforcement discretion policy for substances in Category 1. Even Category 1 substances are only under enforcement discretion, which is short of full authorization
I always encourage patients to ask questions and share any concerns they have
As a tri-agonist, it targets three different receptors: the glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors